Doximity (DOCS) reported strong financial results for the fourth quarter and fiscal year, with revenue hitting $145 million for the quarter, a 5% increase year-over-year, and $645 million for the year, reflecting a 13% growth. Notably, the company achieved its first-ever nine-digit free cash flow quarter at $107 million, while adjusted EBITDA margins remained robust at 45% for the quarter and 55% for the year. However, the non-GAAP gross margin dipped slightly to 89%, attributed to rising AI compute costs.
The company is focusing on expanding its AI capabilities, with nearly half of its active prescribers now utilizing AI tools. Despite initial demand from pharmaceutical clients, Doximity anticipates minimal AI revenue contributions this fiscal year due to regulatory hurdles. The shift in customer purchasing patterns towards shorter commitments indicates a cautious market environment, which may affect future revenue visibility.
Investors should note that while Doximity is investing heavily in AI and expanding its user base, the near-term revenue outlook remains conservative. The ongoing commitment to AI development could position the company favorably for long-term growth in a burgeoning market.
Source: fool.com